Indications -- HIV Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- HIV

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (139)	7/21/2010 3:25:05 AM
From: Elroy Jetson	of 155

I believe the short 48 week duration of the ABT study does not capture what I believe is the the durability of Truvada when compared with Isentress, which has a low resistance hurdle when compared with Truvada. I believe part of this is due to the relative half-life of the drugs, Viread with median 17 hours serum and 60 hour intracellular, compared with 9 hours serum for Isentress and an ill-defined intracellular range of up to 29 hours. There are known advantages of reduced viral fitness resulting from adapted viral resistance to the shorter-live Emtriva co-drug in Truvada, or the closely related Epivir. The other portion of reduced Isentress durability lies in the limited number of mutations required to obtain resistance. Side-effect wise you have kidney toxicity with Viread compared with inflammatory symptoms in many who try Isentress. It would be great if someone developed a superior complementary therapy to Viread, but I don't see that currently among the contenders. .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next